Edwards Lifesciences Corporation $EW Shares Bought by Kovitz Investment Group Partners LLC

Key Points

• Kovitz Investment Group Partners LLC increased its holdings in Edwards Lifesciences by 21.2%, acquiring an additional 8,762 shares and bringing its total to 50,099 shares worth $3.63 million.
• Edwards Lifesciences reported a Q2 EPS of $0.67, exceeding estimates, with revenue of $1.53 billion, reflecting a year-over-year growth of 11.9%.
• Wall Street analysts show a positive outlook on Edwards Lifesciences, with a consensus rating of "Moderate Buy" and an average price target of $85.90.

Kovitz Investment Group Partners LLC boosted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 21.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,099 shares of the medical research company's stock after acquiring an additional 8,762 shares during the period. Kovitz Investment Group Partners LLC's holdings in Edwards Lifesciences were worth $3,631,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Vega Investment Solutions acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. SouthState Corp purchased a new position in Edwards Lifesciences during the 1st quarter worth $27,000. Rossby Financial LCC acquired a new position in Edwards Lifesciences in the first quarter valued at $29,000. Costello Asset Management INC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $29,000. Finally, Global X Japan Co. Ltd. boosted its stake in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

EW has been the subject of a number of recent research reports. Barclays increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, July 25th. Mizuho raised their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 25th. BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a research note on Tuesday, July 29th. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Finally, Citigroup reissued a "buy" rating and set a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Price Performance

EW stock traded up $0.5650 on Friday, reaching $81.7250. The company had a trading volume of 1,921,092 shares, compared to its average volume of 4,511,394. The company's fifty day moving average is $77.45 and its 200 day moving average is $74.60. The company has a market cap of $47.98 billion, a P/E ratio of 11.76, a PEG ratio of 3.93 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the business posted $0.70 earnings per share. The company's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,584 shares of company stock worth $1,897,762. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.